scholarly journals Shared scheme for assessing drugs for multiple sclerosis: Cost effective provision of effective treatments for multiple sclerosis

BMJ ◽  
2003 ◽  
Vol 326 (7400) ◽  
pp. 1212-1212 ◽  
Author(s):  
J. C Napier
Keyword(s):  
Multiple Sclerosis ◽  
Cost Effective ◽  
Effective Treatments

COST-UTILITY ANALYSIS OF MULTIPLE SCLEROSIS TREATMENT IN THAILAND

2018 ◽  
Vol 34 (6) ◽  
pp. 584-592
Author(s):  
Chalakorn Chanatittarat ◽  
Usa Chaikledkaew ◽  
Naraporn Prayoonwiwat ◽  
Sasitorn Siritho ◽  
Pakamas Pasogpakdee ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cost Effective ◽  
Best Supportive Care ◽  
Quality Adjusted Life Year ◽  
Cost Utility ◽  
Outcome Data ◽  
Essential Medicines ◽  
Sensitivity Analyses ◽  
Lifetime Horizon ◽  
Cost Effective Treatment

Objectives:Although interferon beta-1a (IFNß−1a), 1b (IFNß−1b), and fingolimod have been approved as multiple sclerosis (MS) treatments, they have not yet been included on the National List of Essential Medicines (NLEM) formulary in Thailand. This study aimed to evaluate the cost-utility of MS treatments compared with best supportive care (BSC) based on a societal perspective in Thailand.Methods:A Markov model with cost and health outcomes over a lifetime horizon with a 1-month cycle length was conducted for relapsing–remitting MS (RRMS) patients. Cost and outcome data were obtained from published studies, collected from major MS clinics in Thailand and a discount rate of 3 percent was applied. The incremental cost-effectiveness ratio (ICER) was calculated and univariate and probabilistic sensitivity analyses were performed.Results:When compared with BSC, the ICERs for patients with RRMS aged 35 years receiving fingolimod, IFNβ−1b, and IFNβ−1a were 33,000, 12,000, and 42,000 US dollars (USD) per quality-adjusted life-year (QALY) gained, respectively. At the Thai societal willingness to pay (WTP) threshold of USD 4,500 per QALY gained, BSC had the highest probability of being cost-effective (49 percent), whereas IFNβ−1b and fingolimod treatments showed lower chance being cost-effective at 25 percent and 18 percent, respectively.Conclusions:Compared with fingolimod and interferon treatments, BSC remains to be the most cost-effective treatment for RRMS in Thailand based on a WTP threshold of USD 4,500 per QALY gained. The results do not support the inclusion of fingolimod or interferon in the NLEM for the treatment of RRMS unless their prices are decreased or special schema arranged.

scholarly journals Cladribine tablets are a cost-effective strategy in high-disease activity relapsing multiple sclerosis patients in Iran

2021 ◽  
Author(s):  
Nayyereh Ayati ◽  
Lora Fleifel ◽  
Mohammad Ali Sahraian ◽  
Shekoufeh Nikfar
Keyword(s):  
Multiple Sclerosis ◽  
Cost Effectiveness ◽  
Disease Activity ◽  
Cost Effective ◽  
High Disease Activity ◽  
Sensitivity Analyses ◽  
Life Years ◽  
Multiple Sclerosis Patients ◽  
The Cost ◽  
Relapsing Multiple Sclerosis

Background: Cladribine tablets are the foremost oral immune-reconstitution therapy for high disease activity relapsing multiple sclerosis (HDA-RMS). We aimed to assess the cost-effectiveness of cladribine tablets compared to natalizumab in patients with HDA-RMS in Iran. Methods: A 5-year cohort-based Markov model was developed with 11 expanded disability status score (EDSS) health states, including patients with HDA-RMS as on and off-treatment. All costs were identified from the literature and expert opinion and were measured in Iranian Rial rates, changed to the 2020 USD rate and were discounted by 7.2%. Quality adjusted life years (QALY), discounted by 3.5%, and life years gained (LYG) were adopted to measure efficacy. The final results were presented as incremental cost-effectiveness ratio that was compared to a national willingness to pay (WTP) threshold of 1 to 3 gross domestic product (GDP) per capita. Deterministic and probabilistic sensitivity analyses (D/PSA) were employed to evaluate uncertainty. Results: Cladribine tablets dominated natalizumab and yielded 6,607 USD cost-saving and 0.003 additional QALYs per patient. LYG was comparable. The main cost component was drug acquisition cost in both arms. DSA indicated the sensitivity of the results to the cost discount rates and also the patients’ body weight; while they were less sensitive to the main clinical variables. PSA indicated that cladribine tablets were cost-effective in Iran, with a probability of 57.5% and 58.6% at lower and higher limits of threshold, respectively. Conclusion: Cladribine tablets yielded higher QALYs and lower costs compared to natalizumab, in patients with HDA-RMS in Iran.

Telemedicine and multiple sclerosis: A comprehensive literature review

2019 ◽  
Vol 26 (7-8) ◽  
pp. 400-413 ◽  
Author(s):  
Samuel Yeroushalmi ◽  
Heidi Maloni ◽  
Kathleen Costello ◽  
Mitchell T Wallin
Keyword(s):  
Multiple Sclerosis ◽  
Medical Literature ◽  
Clinical Care ◽  
Cost Effective ◽  
Management Interventions ◽  
Comprehensive Literature Review ◽  
Health Studies ◽  
Boolean Search ◽  
Optimal Implementation

Introduction Patients with multiple sclerosis (pwMS) face barriers accessing specialty care for evaluation and treatment. Telemedicine, the practice of clinical care at a distance with the aid of technology, may be a potential bridge to close the access gap for pwMS separated by distance or disability. The objective of this review was to investigate the types of telemedicine being utilized and overall outcomes for pwMS and their providers. Methods A Boolean search of the medical literature was conducted between January 2000 and January 31, 2018. PubMed, EMBASE, PsycINFO and the Cochrane databases, were used to identify all relevant citations. Two reviewers independently appraised the articles for meeting study criteria and for study quality using the CASP system. Financial costs of the telemedicine applications were assessed. Results A total of 28 studies involving 3252 participants met criteria for inclusion. Telemedicine interventions were classified, and outcomes were assessed systematically by the following categories: general MS care; rehabilitation and exercise; and neuropsychology/mental health. Studies showed a range of outcomes with variable quality. Overall, remote clinical examinations, long-term telemedicine management interventions and telerehabilitation were shown to be beneficial, cost-effective and satisfactory for patients and providers. Discussion Telemedicine is a viable platform for delivering specialty MS care. Remote neurological assessments and several forms of therapy have been shown to be technically feasible. Optimal implementation and barriers to the use of telemedicine in the current healthcare system should be explored.

scholarly journals Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?

2018 ◽  
Vol 4 (2) ◽  
pp. 205521731878376 ◽  
Author(s):  
Zhifeng Mao ◽  
César Álvarez-Gonzalez ◽  
Stefania De Trane ◽  
Ozlem Yildiz ◽  
Christo Albor ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cost Effective ◽  
Cell Leukaemia ◽  
European Medicines Agency ◽  
Middle Income ◽  
Middle Income Countries ◽  
Oral Preparation ◽  
Disease Modifying ◽  
Disease Modifying Treatment ◽  
Phase Ii And Iii

Background A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective The objective of this commentary is to propose a useful cost-effective disease-modifying treatment option for pwMS in LMIC with potential high efficacy and high convenience to the pwMS and treating physician. Viewpoint: We propose using generic 2-chloro-2’-deoxyadenosine (cladribine), a small molecule licensed for treatment of people with hairy cell leukaemia, as a solution of this significant equity imbalance. Cladribine has been shown in phase II and III trials to be a highly effective disease-modifying treatment for pwMS, and its adverse effect profile is comparable with any DMT currently licensed in high-income economies where an oral preparation has recently been licensed by the European Medicines Agency. Conclusion Our viewpoint takes into account experience we have gathered over the past three years in the use of generic cladribine to treat pwMS. Whilst here we focus on MS, there is significant potential for use of cladribine in other conditions that could benefit from its mechanism of action.

scholarly journals How Does Cost-Sharing Impact Spending Growth and Cost-Effective Treatments? Evidence from Deductibles

2020 ◽  
Author(s):  
Claudio Lucarelli ◽  
Molly Frean ◽  
Aliza Gordon ◽  
Lynn Hua ◽  
Mark Pauly
Keyword(s):  
Cost Sharing ◽  
Cost Effective ◽  
Spending Growth ◽  
Effective Treatments
Sign in / Sign up

Export Citation Format

Share Document